Halozyme
HALO
161 hedge funds and large institutions have $909M invested in Halozyme in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 59 increasing their positions, 50 reducing their positions, and 18 closing their positions.
359% more call options, than puts
Call options by funds: $14M | Put options by funds: $3.04M
18% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 50
0% more funds holding
Funds holding: 161 → 161 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
6% less capital invested
Capital invested by funds: $967M → $909M (-$57.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$17.6M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$7.75M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.36M |
| 4 |
SCM
Snyder Capital Management
San Francisco,
California
|
+$5.8M |
| 5 |
First Eagle Investment Management
New York
|
+$4.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$9.18M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$5.47M |
| 3 |
TS
Third Security
Radford,
Virginia
|
-$5.17M |
| 4 |
Renaissance Technologies
New York
|
-$3.55M |
| 5 |
QF
QVT Financial
New York
|
-$1.91M |
HALO Hedge Fund Activity: Q2 2016 in Review
161 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q2 2016, worth a combined $909M — down 6% from $967M a quarter earlier.
Fund positioning in HALO was balanced in Q2 2016: 18 funds opened new positions, 18 closed out, 59 added to existing stakes and 50 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $17.6M. The largest seller was Invesco, cutting an estimated $9.18M.
- 161 institutional investors held Halozyme (HALO) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $909M of Halozyme stock for Q2 2016, down 6% quarter-over-quarter.
- 18 funds opened new Halozyme positions in Q2 2016 and 18 closed out, a net change of 0 holders.
- The largest Halozyme buyer in Q2 2016 was Bank of New York Mellon, an estimated $17.6M added.
- The largest Halozyme seller in Q2 2016 was Invesco, an estimated $9.18M sold.
Based on aggregated 13F filings for Q2 2016.